Skip to content
A10479Assembly2023-2024 Session

Require Foreign Drug Labels

Official title

“Enacts the "foreign drug transparency act"”

Sponsor Jake Ryan BlumencranzAD-15Affects Health
Status
In Assembly Committee
Health
Impact
6/10
Moderate
Passage
0%

Bill progress

Step 2 of 7

In committee · Health

What's happening

The bill requires prescription labels to disclose if drugs were made or compounded abroad, FDA inspection status, and inspection date.

Why it matters

  1. Empowers patients to make informed health decisions. by requiring clear disclosure on prescription labels if a drug was made or compounded abroad, as well as FDA inspection status and date, giving patients more transparency about the origin and oversight of their medications.

  2. Highlights regulatory gaps and potential safety concerns. by specifically requiring larger, more prominent warnings (minimum 14-point font) on labels if a foreign-manufactured drug has not been approved by the FDA's foreign drug inspection program, signaling increased risk or lack of oversight.

  3. Places accountability on pharmacies and pharmacy benefit managers. to track and communicate detailed manufacturing and inspection information, potentially increasing administrative burdens but aiming to foster trust in the drug supply chain.

  4. May influence consumer choice and market dynamics. by making information about foreign manufacturing and regulatory status more visible, which could shape patient preferences, prescriber behavior, and potentially pressure manufacturers to improve compliance with FDA inspections.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Who cares

  • Pharmacy benefit managers

    They would have to disclose to health plans, pharmacies and patients whether a prescription drug was manufactured or compounded abroad, its FDA foreign drug inspection program approval status and its last inspection date.

  • Pharmacies and pharmacists

    Prescription labels would have to include the country of manufacture or compounding, FDA foreign drug inspection information and prominent formatting, with a larger warning if the drug lacks program approval.

  • Patients filling prescriptions

    They would receive manufacturing-origin and inspection information on prescription labels, including a warning for drugs not approved by the FDA foreign drug inspection program.

  • Health plans

    They would receive disclosures from pharmacy benefit managers about foreign manufacture or compounding, FDA foreign drug inspection program approval and the last inspection date.

Headline styles

Require Foreign Drug Labels

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Jake Ryan Blumencranz

Assembly Member · Assembly District 15

Rules

No co-sponsors yet.

History

  1. Referred to health

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

10479

IN ASSEMBLY

May 29, 2024

Introduced by COMMITTEE ON RULES -- (at request of M. of A. Blumencranz) -- read once and referred to the Committee on Health

AN ACT to amend the public health law and the education law, in relation to the labeling of prescriptions that are manufactured or compounded in a foreign country and subject to approval by the federal Food and Drug Administration foreign drug inspection program

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Short title. This act shall be known and may be cited as the "foreign drug transparency act".

§ 2. Subdivision 3 of section 280-a of the public health law, as amended by chapter 128 of the laws of 2022, is amended to read as follows

3. Prescriptions. A pharmacy benefit manager may not substitute or cause the substituting of one prescription drug for another in dispensing a prescription, or alter or cause the altering of the terms of a prescription, except with the approval of the prescriber or as explicitly required or permitted by law, including regulations of the department of financial services or the department of health. The superintendent and commissioner, in coordination with each other, are authorized to promulgate regulations to determine when substitution of prescription drugs may be required or permitted. A pharmacy benefit manager shall disclose to a health plan, pharmacy and patient whether a prescription drug was manufactured or compounded in a foreign country; whether the prescription was approved by the federal food and drug administration foreign drug inspection program; and the date of the last inspection of such prescription drug by the federal food and drug administration foreign drug inspection program.

§ 3. Subdivision 1 of section 6810 of the education law, as amended by section 2 of part V of chapter 57 of the laws of 2012, is amended to read as follows

1. No drug for which a prescription is required by the provisions of the Federal Food, Drug and Cosmetic Act or by the commissioner of health shall be distributed or dispensed to any person except upon a

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD15348-01-4

prescription written by a person legally authorized to issue such prescription. Such drug shall be compounded or dispensed by a licensed pharmacist, and no such drug shall be dispensed without affixing to the immediate container in which the drug is sold or dispensed a label bearing the name and address of the owner of the establishment in which it was dispensed, the date compounded, the number of the prescription under which it is recorded in the pharmacist's prescription files, the name of the prescriber, the name and address of the patient, and the directions for the use of the drug by the patient as given upon the prescription, and the country in which the drug was manufactured or compounded; whether the drug was approved by the federal food and drug administration foreign drug inspection program; and the date of the last inspection of such prescription drug by the federal food and drug administration foreign drug inspection program. Such label shall be emphasized by being highlighted in yellow color or in bold type or both and printed in a minimum of a twelve-point font; if said drug was not approved by the federal food and drug administration foreign drug inspection program, such information shall be contained within the label with a warning sign and in a minimum size fourteen-point font. All labels shall conform to such rules and regulations as promulgated by the commissioner pursuant to section sixty-eight hundred twenty-nine of this article. The prescribing and dispensing of a drug which is a controlled substance shall be subject to additional requirements provided in article thirtythree of the public health law. The words "drug" and "prescription required drug" within the meaning of this article shall not be construed to include soft or hard contact lenses, eyeglasses, or any other device for the aid or correction of vision. Nothing in this subdivision shall prevent a pharmacy from furnishing a drug to another pharmacy which does not have such drug in stock for the purpose of filling a prescription.

§ 4. This act shall take effect immediately.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.